Tonix Pharmaceutical

Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of Fibromyalgia

Email Print Friendly Share
September 03, 2020 09:00 ET | Source: Tonix Pharmaceuticals Holding Corp.


Interim Analysis Results from Ongoing Phase 3 RELIEF Study Expected in September; Topline Results Expected in Fourth Quarter 2020
Positive Outcomes in Both Trials Would Support Submission of NDA in Second Half 2022​
 
Southern Research and Tonix make headway in Covid-19 vaccine
Tonix up 7%
 

Tonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia​

 
Tonix Pharmaceuticals Holding Corp. ( NASDAQ: TNXP ) El Dr. Seth Lederman le dice a Proactive que la compañía biofarmacéutica en etapa clínica ha formado un acuerdo de licencia exclusivo para desarrollar un posible tratamiento para el coronavirus, TNX-3500, de OyaGen, Inc., una compañía de investigación de biotecnología preclínica. El Dr. Lederman dice que el TNX-3500 es '65 veces más potente 'que el Remdesivir de Gilead, in vitro, para inhibir el coronavirus. Agrega que el grupo está muy emocionado de trasladar TNX-3500 a estudios con animales y, posteriormente, a pruebas clínicas en humanos.

www.proactiveinvestors.com

Tonix Pharmaceuticals forms exclusive licensing agreement develop a potential coronavirus treatment

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Dr Seth Lederman tells Proactive the clinical-stage biopharmaceutical company has formed an exclusive...
www.proactiveinvestors.com
 

Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting​

Confirmatory Phase 3 Study, RALLY, Ongoing with Interim Analysis Expected in Third Quarter 2021​

June 03, 2021 07:00 ET | Source: Tonix Pharmaceuticals Holding Corp.
www.globenewswire.com

Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Confirmatory Phase 3 Study, RALLY, Ongoing with Interim Analysis Expected in Third Quarter 2021...
www.globenewswire.com www.globenewswire.com
 
You must log in or register to reply here.

Similar threads

P
Bionor with HIV and AIDS cure
2
Replies
27
Views
9K
Promille
P
S
For Biotech fans
Replies
4
Views
3K
ChartMan
C
A
ANX - Hot on Wallstreet Tip
Replies
0
Views
2K
AmexHunter
A
D
I had a good day
Replies
14
Views
3K
Day-to-day
D
H
Heb -
Replies
1
Views
2K
HotstockBull
H
Top